ClinicalTrials.gg
CompletedNCT01324752Updated Dec 21, 2012

A Drug-Drug Interaction Study of Losartan and PA21

A Phase 1 interventional study of PA21 and Losartan with Food and No PA21; Losartan with food in Drug Interaction Potentiation, sponsored by Vifor Pharma. Completed at 1 site in United States. Open to participants aged 20 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-12-21.

Sponsored by Vifor Pharma (part of CSL Limited) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
20 Years to 50 Years
Sex
All
01

Study summary

The purpose of this study is to determine if Losartan potassium is affected by PA21.

02

Conditions studied

  • Drug Interaction Potentiation

Keywords

  • Drug-drug interaction
  • Pharmacokinetics
  • PA21
03

In context

Lead sponsor

Vifor Pharma is the lead sponsor of 22 studies on the registry; none are open to participants now.

First submitted before Vifor Pharma became part of CSL Limited.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy volunteers
  • Written

Exclusion criteria

Exclusion Criteria:

  • No significant medical conditions
  • Pregnancy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    PA21 and Losartan with food

    Drug: PA21 and Losartan with Food

  • Experimental
    No PA21; Losartan with food

    Drug: No PA21; Losartan with food

  • Experimental
    PA21 with food and Losartan 2 hrs later

    Drug: PA21 with food and Losartan 2 hours later

Interventions

  • DrugPA21 and Losartan with Food

    Drug pages: PA21 · Losartan

    The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Losartan will be 100 mg/day.

  • DrugNo PA21; Losartan with food

    The maximum dose of Losartan will be 100 mg/day.

  • DrugPA21 with food and Losartan 2 hours later

    The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Losartan will be 100 mg/day.

06

What researchers measure

Primary outcomes

  1. Effect of PA21 on Losartan potassium

    To assess the effect, if any, of PA21 on Losartan potassium exposure

    Time frame: PK assessment on Day 0, 11, 22

Secondary outcomes

  1. Effect of PA21 on the active metabolite of Losartan potassium

    To assess the effect, if any, of PA21 on the active metabolite of Losartan potassium

    Time frame: PK assessment on Day 0, 11, 22

07

Study locations

1 site
  • ACRI- Phase 1
    Anaheim, California 92801, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2011, a primary completion of Jun 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2011
First posted
Mar 29, 2011
Start
Mar 2011
Primary completionActual
Jun 2011
CompletionActual
Jun 2011
Last update
Dec 21, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 21, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01324752
Lead sponsor
Vifor Pharma
Responsible party
Sponsor
First posted
Mar 29, 2011
Start date
Mar 2011
Primary completion
Jun 2011
Completion
Jun 2011
Last update
Dec 21, 2012

Study contacts

Peter J Winkle, MD
principal investigator · ACRI - Phase 1 (Advanced Clinical Research Institute)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: PA21 · Losartan

Start the discussion